Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Omeprazole Intermediates With High Purity Omeprazole CAS 73590-58-6 Omeprazole Hydroxy Compound CAS 86604-78-6 Omeprazole Chloride Compound CAS 86604-75-3 Omeprazole Sulfide CAS 73590-85-9 2-Mercapto-5-Methoxybenzimidazole CAS 37052-78-1 2-Cyano-3-Methylpyridine CAS 20970-75-6 2,3,5-Trimethylpyridine CAS 695-98-7| Item | Specifications |
| Appearance | White to Off-White Powder or Crystals |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | <1.00% |
| Residue on Ignition | <0.20% |
| Heavy Metals (as Pb) | <20ppm |
| Single Impurity | <0.50% |
| Total Impurities | <1.00% |
| Infrared Spectrum | Conforms to Structure |
| Proton NMR Spectrum | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Omeprazole / Esomeprazole |
Description:
Specifications:
Package & Storage:
| Chemical Name | Omeprazole Sulfide |
| Synonyms | Ufiprazole; Omeprazole Sulfur Ether; Esomeprazol EP Impurity C; Omeprazole EP Impurity C; 5-Methoxy-2-[[(4-Methoxy-3,5-Dimethyl-2-Pyridyl)methyl]thio]benzimidazole; 5-Methoxy-2-{[(4-Methoxy-3,5-Dimethyl-2-Pyridinyl)methyl]thio}-1H-Benzimidazole |
| CAS Number | 73590-85-9 |
| CAT Number | RF-PI1914 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C17H19N3O2S |
| Molecular Weight | 329.42 |
| Melting Point | 122.0 to 126.0℃ |
| Solubility | Soluble in Methanol |
| Density | 1.28±0.10 g/cm3 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Omeprazole Sulfide (CAS: 73590-85-9) is an intermediate used in the production of the gastric proton pump inhibitors, Omeprazole (CAS: 73590-58-6) and Esomeprazole (CAS: 119141-88-7), Esomeprazole Sodium (CAS: 161796-78-7). As a degradation product, it is reported to be a direct-acting inhibitor of cytochrome P450 2C19 in pooled human liver microsomes (IC50 = 9.7 μM). Omeprazole Sulfide is a metabolite of Omeprazole. Esomeprazole Sodium is the sodium salt form of esomeprazole. It is a commonly used anti-ulcer drug, which was first successfully developed by the Swedish company Astra Zeneca first. It belongs to a proton pump inhibitor. The proton pump inhibitor is the primary choice for treating peptic ulcer, gastro-oesophageal reflux disease and other acid-related diseases. Currently commonly clinically used PPI include five kinds: Omeprazole, Lansoprazole, Rabeprazole, Pantoprazole and Esomeprazole. As the first PPI, the omeprazole’s drug efficacy in treating acid-related diseases has been widely recognized. Esomeprazole is the S-isomer of Omeprazole, which can reduce gastric acid secretion by specific targeting mechanism. It is the specific inhibitor for the proton pump inhibitor in the parietal cell. Owing to the metabolic advantage of esomeprazole, it has a higher bioavailability and more consistent pharmacokinetics than its counterpart, Omeprazole Sodium, increasing the drug that reaches the proton pump. Its role of gastric acid control is much better than other proton pumps inhibitors such as Lansoprazole, Pantoprazole, and Rabeprazole.
